F2G’s Global Strategy for Rare Fungal Infection Trials

Key Takeaways

• Olorofim shows 27% three‑month mortality vs 90% historical in aspergillosis
• Phase III OASIS trial completed enrollment of 225 patients across 140 sites
• Shionogi paid $100 million upfront and funds half of Phase III costs
• Managed‑access program already provided free olorofim to over 450 patients worldwide
• Global trial success depends on diagnostic capacity, expertise, and patient incidence

Pulse Analysis

The antifungal landscape has long been dominated by azoles, polyenes and echinocandins, leaving clinicians with few options for invasive mold infections that carry mortality rates above 80 percent. Olorofim, the first member of the orotomide class, blocks fungal dihydroorotate dehydrogenase, starving the pathogen of pyrimidines and delivering potent fungicidal activity with a safety profile that avoids the nephrotoxicity of amphotericin B. Its oral formulation and selectivity for fungal enzymes make it a compelling candidate to fill a therapeutic void that has persisted for decades.

Running a Phase III trial for a rare disease demands more than scientific rigor; it requires a precise global infrastructure. F2G opened roughly 140 sites across the United Kingdom, United States and Austria, enrolling an average of 1.4 patients per site to reach 225 participants in the OASIS study. Success hinged on sites equipped with rapid galactomannan and PCR diagnostics, clinicians experienced in managing drug‑drug interactions, and a patient population dense enough to meet enrollment targets. The trial’s design—comparing olorofim to AmBisome—also forced sponsors to consider local availability of the comparator drug, further underscoring the importance of regional expertise.

Strategic collaboration with Shionogi amplifies F2G’s commercial reach while sharing development risk. The Japanese partner contributed a $100 million upfront payment and is covering 50 percent of Phase III expenses, securing rights to commercialize olorofim across Europe and Asia‑Pacific. Together, the companies have launched a compassionate‑use program that has already provided free treatment to more than 450 patients worldwide, building real‑world evidence ahead of regulatory filing. With FDA Breakthrough Therapy, orphan‑drug and QIDP designations in place, a positive data readout in mid‑2026 could pave the way for a 2027 U.S. launch, potentially redefining standards of care for rare invasive fungal infections.